DocCheck AG (DE:AJ91)
XETRA:AJ91
Want to see DE:AJ91 full AI Analyst Report?
Top Page
DocCheck AG
(XETRA:AJ91)
Select Model
Select Model
Rating:68Neutral
Price Target:
€15.00
▲(19.05% Upside)
Action:Downgraded
Date:05/22/26
The score is supported most by attractive valuation (low P/E and high dividend yield) and a strong, low-leverage balance sheet. Offsetting this are inconsistent revenue momentum and weaker 2025 cash-flow quality, while technicals are mixed with near-term softness but longer-term trend support.
Positive Factors
Low leverage / strong balance sheet
DocCheck’s very low leverage (debt ≈ 0.10x equity in 2025) and sizeable equity relative to assets provide durable financial flexibility. This conservatism reduces refinancing and solvency risk, supports investment or dividend capacity, and cushions the business during cyclical revenue swings.
Negative Factors
Volatile revenue and 2025 decline
The sustained revenue volatility and the explicit decline in 2025 weaken predictability of top‑line performance. For a B2B services provider, uneven sales hinder capacity planning and limit the ability to steadily scale margins or fund multi‑year growth initiatives without relying on one‑off measures.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
DocCheck’s very low leverage (debt ≈ 0.10x equity in 2025) and sizeable equity relative to assets provide durable financial flexibility. This conservatism reduces refinancing and solvency risk, supports investment or dividend capacity, and cushions the business during cyclical revenue swings.
Read all positive factors
DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€66.97M
Dividend Yield6.36%
Average Volume (3M)1.04K
Price to Earnings (P/E)5.4
Beta (1Y)0.57
Revenue Growth2.84%
EPS Growth0.96%
CountryDE
Employees373
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)1.05
Shares Outstanding5,073,816
10 Day Avg. Volume577
30 Day Avg. Volume1,041
Financial Highlights & Ratios
PEG Ratio12.17
Price to Book (P/B)1.50
Price to Sales (P/S)1.13
P/FCF Ratio23.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DocCheck AG Business Overview & Revenue Model
Company Description
DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for he...
How the Company Makes Money
DocCheck AG primarily makes money by selling B2B digital marketing and communication services to clients in the healthcare and life sciences industries. Key revenue streams typically include (1) paid advertising and sponsorship placements targeted...
DocCheck AG Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.32M | 53.79M | 53.41M | 60.90M | 85.92M |
| Gross Profit | 12.28M | 10.53M | 12.97M | 14.08M | 21.54M |
| EBITDA | 10.39M | 10.18M | 9.38M | 13.38M | 20.09M |
| Net Income | 5.33M | 5.28M | 2.27M | 6.29M | 11.40M |
Balance Sheet | |||||
| Total Assets | 55.68M | 60.86M | 56.14M | 63.28M | 60.25M |
| Cash, Cash Equivalents and Short-Term Investments | 18.54M | 21.02M | 17.52M | 15.66M | 21.52M |
| Total Debt | 4.16M | 5.01M | 5.85M | 7.07M | 7.03M |
| Total Liabilities | 14.07M | 20.78M | 18.11M | 23.86M | 22.08M |
| Stockholders Equity | 41.61M | 40.08M | 37.33M | 38.57M | 37.31M |
Cash Flow | |||||
| Free Cash Flow | 2.61M | 6.82M | 5.62M | -557.91K | 6.90M |
| Operating Cash Flow | 6.14M | 7.82M | 7.51M | 5.89M | 10.92M |
| Investing Cash Flow | -3.81M | -1.48M | -1.93M | -4.92M | -4.39M |
| Financing Cash Flow | -4.88M | -3.50M | -4.60M | -5.81M | -5.86M |
DocCheck AG Technical Analysis
Neutral
12.60
Price Trends
12.88
Positive
12.89
Positive
12.54
Positive
Market Momentum
0.60
Positive
45.16
Neutral
50.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Neutral. The current price of 12.6 is below the 20-day moving average (MA) of 14.36, below the 50-day MA of 12.88, and above the 200-day MA of 12.54, indicating a neutral trend. The MACD of 0.60 indicates Positive momentum. The RSI at 45.16 is Neutral, neither overbought nor oversold. The STOCH value of 50.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:AJ91.
DocCheck AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €41.86M | 14.26 | 13.44% | 3.86% | -6.92% | -67.82% | |
68 Neutral | €66.97M | 5.43 | 13.28% | 6.36% | 2.84% | 0.96% | |
60 Neutral | €1.44B | 50.01 | 4.19% | 0.20% | 1.16% | -43.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | €69.38M | -16.59 | -52.70% | ― | 7.29% | 47.59% |
* Healthcare Sector Average
DE:AJ91
DocCheck AG
13.20
1.94
17.23%
DE:COP
CompuGroup Medical
27.30
5.71
26.47%
DE:M3V
MeVis Medical Solutions
23.00
-1.86
-7.50%
DE:V3V
VITA 34
3.98
0.00
0.00%
DE:HAEK
HAEMATO AG
13.00
0.55
4.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.